SCHEMBL1335863

SCHEMBL1335863

COc1c2c(c3n(c1=O)CCCCN(CCO)C3=O)CCN(Cc1ccc(F)c(Cl)c1)C2=O

nearest known ligand 0.39

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.36
ADORA2A P29274 1/20 0.36
AKR1B1 P15121 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
P2RX7 Q99572 6/20 0.33
WDR5 P61964 2/20 0.33
PREP P48147 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1337786 0.90 MAOB (0.36) MAOBADORA2AAKR1B1P2RX7WDR5
SCHEMBL1338165 0.90 P2RX7 (0.35) MAOBADORA2AP2RX7SMN1; SMN2
SCHEMBL1337557 0.90 P2RX7 (0.34) MAOBADORA2AAKR1B1P2RX7WDR5
SCHEMBL2027046 0.89 AKR1B1 (0.43) MAOBADORA2AAKR1B1MEN1KMT2A
SCHEMBL1338285 0.88 MAOB (0.34) MAOBADORA2AAKR1B1P2RX7WDR5
SCHEMBL1335854 0.88 AKR1B1 (0.37) MAOBADORA2AAKR1B1MEN1KMT2A
SCHEMBL1337827 0.87 PKM (0.37) MAOBADORA2AP2RX7SMN1; SMN2
SCHEMBL4793599 0.85 PREP (0.34) MAOBADORA2AAKR1B1P2RX7WDR5
SCHEMBL3491744 0.84 AKR1B1 (0.35) MAOBADORA2AAKR1B1KMT2AP2RX7
SCHEMBL12129209 0.83 AKR1B1 (0.36) MAOBADORA2AAKR1B1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1881825-B1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME (US) 2013-07-24 EP disclosed
US-20130178468-A1 HIV INTEGRASE INHIBITORS VACCA JOSEPH P (US) 2013-07-11 US disclosed
US-8293731-B2 HIV integrase inhibitors Merck Sharp + Dohme Corp. (US) 2012-10-23 US disclosed
US-20110275621-A1 HIV INTEGRASE INHIBITORS SCHERING CORPORATION 2011-11-10 US disclosed
US-7968564-B2 HIV integrase inhibitors MERCK SHARP & DOHME CORP. (US) 2011-06-28 US disclosed
US-20100204201-A1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-08-12 US disclosed
US-7741315-B2 HIV integrase inhibitors MERCK SHARP & DOHME CORP. (US) 2010-06-22 US disclosed
US-20090054399-A1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME CORP. 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054399-A1 HIV INTEGRASE INHIBITORS REV1, POLR1A, POLR2H MAOB 1775/4885ADORA2A 3202/4885AKR1B1 683/4885
US-20100204201-A1 HIV INTEGRASE INHIBITORS REV1, CDKN1A, CCNI MAOB 1926/4885ADORA2A 3500/4885AKR1B1 858/4885
US-20130178468-A1 HIV INTEGRASE INHIBITORS REV1, CDKN1A, CCNI MAOB 1926/4885ADORA2A 3500/4885AKR1B1 858/4885
US-20110275621-A1 HIV INTEGRASE INHIBITORS REV1, CDKN1A, CCNI MAOB 1926/4885ADORA2A 3500/4885AKR1B1 858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.